Abstract:Pancreatic ductal adenocarcinoma (PDAC), a leading cause of cancer mortality in the United States, presents significant treatment challenges due to its late diagnosis and poor prognosis. Despite advances, the five-year survival rates remain dismally low, with only a fraction of patients eligible for potentially curative surgical interventions. This review aims to comprehensively examine the current landscape of targeted therapies in PDAC, focusing on recent developments in precision medicine approaches. We explore various molecular targets, including KRAS mutations, DNA damage repair deficiencies, mismatch repair pathway alterations, and rare genetic fusions. The review discusses emerging therapies, such as PARP inhibitors, immune checkpoint inhibitors, and novel targeted agents, like RET and NTRK inhibitors. We analyze the results of key clinical trials and highlight the potential of these targeted approaches in specific patient subgroups. Recent developments in PDAC research have emphasized precision oncology, facilitated by next-generation sequencing and the identification of genetic and epigenetic alterations. This approach tailors treatments to individual genetic profiles, improving outcomes and reducing side effects. Significant strides have been made in classifying PDAC into various subtypes, enhancing therapeutic precision. The identification of specific mutations in genes like KRAS, along with advancements in targeted therapies, including small molecule inhibitors, offers new hope. Furthermore, emerging therapies targeting DNA repair pathways and immunotherapeutic strategies also show promising results. As research evolves, integrating these targeted therapies with conventional treatments might improve survival rates and quality of life for PDAC patients, underscoring the shift towards a more personalized treatment paradigm.

Precision Targeting Strategies in Pancreatic Cancer: The Role of Tumor Microenvironment

The Role of Tumor Microenvironment in Pancreatic Cancer Immunotherapy: Current Status and Future Perspectives

Decoding the Intricate Landscape of Pancreatic Cancer: Insights into Tumor Biology, Microenvironment, and Therapeutic Interventions

New Potential Therapeutic Strategy of Pancreatic Cancer via Targeting the Tumor Microenvironment

Focus on Pancreatic Cancer Microenvironment

The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities

Targeting tumor immunosuppressive microenvironment for pancreatic cancer immunotherapy: Current research and future perspective

Pancreatic ductal adenocarcinoma cells reshape the immune microenvironment: Molecular mechanisms and therapeutic targets

Tumor microenvironment in chemoresistance, metastasis and immunotherapy of pancreatic cancer.

Pancreatic ductal adenocarcinoma microenvironment: Soluble factors and cancer associated fibroblasts as modulators of NK cell functions

Crosstalk between the Tumor Microenvironment and Immune System in Pancreatic Ductal Adenocarcinoma: Potential Targets for New Therapeutic Approaches

Targeted Therapy for Highly Desmoplastic and Immunosuppressive Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma

Management of Pancreatic Cancer and Its Microenvironment: Potential Impact of Nano-Targeting

Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target

Clinical Evaluation of the Pancreatic Cancer Microenvironment: Opportunities and Challenges

Immunosuppression, Immune Escape, and Immunotherapy in Pancreatic Cancer: Focused on the Tumor Microenvironment

Combination, Modulation and Interplay of Modern Radiotherapy with the Tumor Microenvironment and Targeted Therapies in Pancreatic Cancer: Which Candidates to Boost Radiotherapy?

Targeting the Tumor Microenvironment for Pancreatic Ductal Adenocarcinoma Therapy.

Recent advances in drug delivery and targeting for the treatment of pancreatic cancer

Role of the Tumor Microenvironment in Regulating Pancreatic Cancer Therapy Resistance

Targeted Therapies in Pancreatic Cancer: A New Era of Precision Medicine